Evidence map›Paper›PMID 26307669›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016

Syndecan 4 Mediates Nrf2-dependent Expansion of Bronchiolar Progenitors That Protect Against Lung Inflammation.

Arif Santoso, Toshiaki Kikuchi, Naoki Tode, Taizou Hirano, Riyo Komatsu, Triya Damayanti, Hozumi Motohashi, Masayuki Yamamoto, Tetsuhito Kojima, Toshimitsu Uede and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Arif SantosoDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshiaki KikuchiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoki TodeDepartment of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.
Taizou HiranoDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Riyo KomatsuDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Triya DamayantiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hozumi MotohashiDepartment of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Masayuki YamamotoDepartment of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tetsuhito KojimaDepartment of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Toshimitsu UedeDivision of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Toshihiro NukiwaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPHokkaido University · JPNagoya University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of lung progenitors for regenerative medicine appears promising, but their biology is not fully understood. Here, we found anti-inflammatory attributes in bronchiolar progenitors that were sorted as a multipotent subset of mouse club cells and found to express secretory leukocyte protease inhibitor (SLPI). Notably, the impaired expression of SLPI in mice increased the number of bronchiolar progenitors and decreased the lung inflammation. We determined a transcriptional profile for the bronchiolar progenitors of Slpi-deficient mice and identified syndecan 4, whose expression was markedly elevated as compared to that of wild-type mice. Systemic administration of recombinant syndecan 4 protein caused a substantial increase in the number of bronchiolar progenitors with concomitant attenuation of both airway and alveolar inflammation. The syndecan 4 administration also resulted in activation of the Keap1-Nrf2 antioxidant pathway in lung cells, which is critically involved in the therapeutic responses to the syndecan 4 treatment. Moreover, in 3D culture, the presence of syndecan 4 induced differentiated club cells to undergo Nrf2-dependent transition into bronchiolar progenitors. Our observations reveal that differentiative switches between bronchiolar progenitors and club cells are under the Nrf2-mediated control of SLPI and syndecan 4, suggesting the possibility of new therapeutic approaches in inflammatory lung diseases.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBleomycinBronchiolesCell DedifferentiationCytoskeletal ProteinsGene Expression RegulationKelch-Like ECH-Associated Protein 1MiceNaphthalenesNF-E2-Related Factor 2PneumoniaRecombinant ProteinsSecretory Leukocyte Peptidase InhibitorSignal TransductionStem CellsAdaptor Proteins, Signal TransducingBleomycinCytoskeletal ProteinsKeap1 protein, mouseKelch-Like ECH-Associated Protein 1naphthaleneNaphthalenesNfe2l2 protein, mouseNF-E2-Related Factor 2Recombinant ProteinsSdc4 protein, mouseSecretory Leukocyte Peptidase InhibitorSlpi protein, mouseSyndecan-4

Identifiers

PMID26307669
PMCPMC4754542
OpenAlexW1168578519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.